NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
71 trialsNCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT04739761 2026-02-11
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT06057168 2026-01-29
GDX-44-016
Guerbet
Phase 3 Completed
NCT06098248 2025-12-15
cCeLLExvivo
VPIX Medical
Phase NA Terminated
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT04410133 2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3 Completed
NCT04410367 2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2 Completed
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT04479241 2025-06-05
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
Phase 2 Completed
NCT02392078 2025-04-24
LAANTERN
Monteris Medical
Completed
NCT03632135 2025-04-15
CSCRGBM
Cordgenics, LLC
Phase 3 Completed
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT03579602 2024-06-27
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Blaze Bioscience Inc.
Phase 2/3 Completed
NCT03250299 2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
Phase 1 Terminated
NCT02014844 2024-05-29
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ImmunityBio, Inc.
Phase 2 Completed
NCT03257631 2024-04-16
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 2 Completed
NCT01651078 2024-04-15
LAASR
Monteris Medical
Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT01491893 2023-09-28
PVSRIPO
Istari Oncology, Inc.
Phase 1 Completed
NCT02614794 2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT03911869 2023-05-31
POLARIS
Pfizer
Phase 2 Terminated
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT00312728 2023-01-06
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Phase 2 Completed
NCT02858895 2022-10-24
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
Phase 2 Completed
NCT00479765 2022-06-22
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGelâ„¢ in Subjects With Recurrent Glioma
Boston Scientific Corporation
Phase 1/2 Terminated
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT03332589 2022-05-20
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Spirita Oncology, LLC
Phase 1 Terminated
NCT02154529 2022-04-27
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Kadmon Corporation, LLC
Phase 1/2 Terminated
NCT02616393 2022-03-16
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation, LLC
Phase 2 Completed
NCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT01677741 2021-11-24
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Novartis
Phase 1/2 Completed
NCT02844439 2021-09-22
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Kadmon Corporation, LLC
Phase 2 Completed
NCT02765165 2021-07-23
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
Phase 1/2 Terminated
NCT02308020 2020-12-19
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Eli Lilly and Company
Phase 2 Completed
NCT00395863 2020-11-05
Multihance at 3 Tesla (3T) in Brain Tumors
Bracco Diagnostics, Inc
Phase 4 Completed
NCT02038218 2020-09-16
DM-CHOC-PEN
DEKK-TEC, Inc.
Phase 2 Completed
NCT02276053 2020-06-01
VIBES
UCB Pharma
Completed
NCT02343406 2020-05-22
INTELLANCE-2
AbbVie
Phase 2 Completed
NCT02336451 2020-04-21
Ascend-7
Novartis
Phase 2 Completed
NCT00525590 2020-03-16
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
Eisai Inc.
Phase 2 Completed
NCT01349036 2020-03-03
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
Daiichi Sankyo
Phase 2 Terminated
NCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed